Drug intelligence / Profile preview

MP1000

Development stage: Preclinical
Lead developer: Machavert Pharmaceuticals
Modality: Small Molecules

Overview

MP1000 is a bioactive phospholipid drug candidate being developed by Machavert Pharmaceuticals for the treatment of cancer. It is designed to target KRAS mutant solid tumors and hematological malignancies. The drug is part of Machavert's proprietary bioactive phospholipid platform, which aims to provide precision medicine options for cancers driven by KRAS mutations, which account for a significant portion of all human cancers. Preclinical data has shown anti-tumor activity in various models, and as of 2018, the compound was undergoing IND-enabling studies to support entry into human clinical trials.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on MP1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MP1000.

Explore the full profile